Showing results (491-500 of 523) with videos related to
Sort By:
Pageof 53
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway InhibitorsNaoual Menssouri, Loïc Poiraudeau, Carole Helissey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung CancerSandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2026
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLCMay-Lucie Meyer, Solange Peters, Hossein Borghaei, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.Cancer Discovery|June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancerWilliam J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.Pageof 53